Biomarin

BioMarin talks down worries on gene therapy data differences
Biopharma Dive
Tue, 09/10/19 - 11:39 pm
Biomarin
gene therapy
hemophilia A
valrox
BioMarin's Roller Coaster Continues
Yahoo/Motley Fool
Tue, 08/6/19 - 11:00 am
Biomarin
earnings
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Fri, 08/2/19 - 10:37 am
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy
Endpoints
Mon, 07/8/19 - 08:13 pm
Biomarin
hemophilia A
gene therapy
FDA
Sangamo
Pfizer
Sangamo backs up early success for hemophilia gene therapy
Biopharma Dive
Sat, 07/6/19 - 01:36 pm
Sangamo
gene therapy
hemophilia A
SB-525
Pfizer
Spark Therapeutics
Biomarin
How BioMarin May Revolutionize the Hemophilia Treatment Market
Motley Fool
Tue, 05/28/19 - 11:25 pm
Biomarin
gene therapy
hemophilia A
valrox
BioMarin Isn't a "Gene Therapy Company"
Motley Fool
Wed, 05/1/19 - 11:38 pm
Biomarin
earnings
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Mon, 04/22/19 - 10:34 am
Concert Pharmaceuticals
Horizon Pharma
Edwards Lifesciences
Zimmer Biomet
Genfit
Precision Biosciences
Boston Scientific
AbbVie
Alexion
Bristol-Myers Squibb
Baxter
Biomarin
AtriCure
Biogen
Seattle Genetics
IPOs
earnings
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Sun, 03/3/19 - 07:12 pm
Europe
CHMP
AbbVie
Akcea
Biomarin
Sanofi
Pfizer
drug approvals
Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Yahoo/Guru Focus
Sun, 02/24/19 - 11:36 pm
M&A
Merck
Biogen
Biomarin
Eli Lilly
Bristol-Myers Squibb
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
Wed, 02/20/19 - 11:59 am
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
Mon, 12/10/18 - 09:50 am
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
Sat, 10/20/18 - 11:16 pm
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
3 Biotech Stocks With Virtual Monopolies
Motley Fool
Wed, 10/3/18 - 11:53 am
Alexion Pharmaceuticals
Biomarin
Vertex Pharmaceuticals
Express Scripts staking out million-dollar gene therapies
Reuters
Wed, 08/15/18 - 10:32 pm
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
Motley Fool
Tue, 08/7/18 - 11:43 pm
Biomarin
earnings
BioMarin Begins Pediatric Study on Achondroplasia Candidate
Yahoo/Zacks.com
Sat, 06/16/18 - 01:30 pm
Biomarin
clinical trials
vosoritide
achrondoplasia
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
CP Wire
Fri, 05/25/18 - 09:15 am
Biomarin
Palynziq
PKU
FDA

Pages